EGFR Activation Constitutes an Adaptive Response to BRAF Inhibitor Therapy

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-rw2014-079
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Unresponsiveness of Colon Cancer to BRAF(V600E) Inhibition Through Feedback Activation of EGFR

Nature
Multidisciplinary
2012English

Regarding BRAF-inhibitor Therapy of Primary Ameloblastoma

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Nuclear MedicineRadiologyOral SurgeryImagingDentistryForensic MedicinePathologySurgery
2016English

Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2

Cancer Cell
Cancer ResearchOncologyCell Biology
2016English

Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor

OncoTargets and Therapy
OncologyPharmacology
2016English

BRAF; Epidermal Growth Factor Receptor (EGFR)

Science-Business eXchange
2012English

Minocycline Improves the Efficacy of EGFR Inhibitor Therapy: A Hypothesis

Frontiers in Oncology
Cancer ResearchOncology
2016English

EGFR Gene Copy Number Assessment From Areas With Highest EGFR Expression Predicts Response to Anti-Egfr Therapy in Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2011English

Heat-Shock Protein 27 (HSP27, HSPB1) Is Synthetic Lethal to Cells With Oncogenic Activation of MET, EGFR and BRAF

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2017English

Ineffective Anti PD-1 Therapy After BRAF Inhibitor Failure in Advanced Melanoma

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy